| James R Eskew, MD | |
|
4315 James Casey St, Suite 300, Austin, TX 78745-3365 | |
| (512) 444-7944 | |
| (512) 444-7946 |
| Full Name | James R Eskew |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 47 Years |
| Location | 4315 James Casey St, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104912021 | NPI | - | NPPES |
| 120193102 | Medicaid | TX | |
| 88690J | Other | TX | BCBS |
| 120193106 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | E8456 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St David's South Austin Medical Center | Austin, TX | Hospital |
| St David's Medical Center | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Butler And Burns Ear Nose And Throat Associates | 5496668238 | 39 |
News Archive
Mylan Inc. today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020, subject to market and other conditions. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued Senior Notes due 2020 will be treated as a single class of notes under the indenture.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 8 days ago
| Entity Name | Butler & Burns Ear Nose & Throat Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174505473 PECOS PAC ID: 5496668238 Enrollment ID: O20031118000766 |
News Archive
Mylan Inc. today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020, subject to market and other conditions. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued Senior Notes due 2020 will be treated as a single class of notes under the indenture.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James R Eskew, MD 3705 Medical Pkwy, Suite 320, Austin, TX 78705-1019 Ph: (512) 454-0392 | James R Eskew, MD 4315 James Casey St, Suite 300, Austin, TX 78745-3365 Ph: (512) 444-7944 |
News Archive
Mylan Inc. today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020, subject to market and other conditions. The notes are being offered as additional notes under an existing indenture under which Mylan issued $700 million aggregate principal amount of Senior Notes due 2020 on May 19, 2010. The notes to be issued in this offering and the previously issued Senior Notes due 2020 will be treated as a single class of notes under the indenture.
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer.
GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
A new paper by Thomas J. Albin, PE, CPE, of High Plains Engineering Services in Minneapolis, Minnesota, USA, confirms that observational assessment tools, often called checklists, used to assess risk factors such as wrist extension and motion repetition, can be valid tools in identifying work-related risk factors for musculoskeletal injuries.
The state of Kansas' largest insurance company has decided it doesn't want to participate in Gov. Sam Brownback's plan to move Medicaid patients into privatized managed-care programs. In a letter addressed "Dear provider," Angie Strecker, director of institutional relations for Blue Cross Blue Shield of Kansas, said the insurer "has decided not to submit a proposal to the state to be a Medicaid contractor."
› Verified 8 days ago
Robert A. Williamson Jr., M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6811 Austin Center Blvd, Suite 300, Austin, TX 78731 Phone: 512-346-8888 Fax: 512-406-7321 | |
Dr. Jeffrey S Zapalac, M.D., F.A.C.S. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy, Suite 310, Austin, TX 78705 Phone: 512-458-6391 Fax: 512-390-4091 | |
Dr. Joel William Jones, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 9835 N Lake Creek Pkwy, Austin, TX 78717 Phone: 832-822-0629 | |
Dr. Tibor Ruff, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 40 N Interstate 35 Apt 9d1, Austin, TX 78701 Phone: 512-947-4612 | |
Kent P Jones, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 6811 Austin Center Blvd # 300, Austin, TX 78731 Phone: 512-346-8888 Fax: 512-344-0340 | |
David Crockett Teller, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 7901 Metropolis Dr, Austin, TX 78744 Phone: 512-823-4880 Fax: 512-823-4155 |